Johan F. Vansteenkiste, MD, PhD, on NSCLC: Immunotherapy and Targeted Treatments
ESMO 2018 Congress
Johan F. Vansteenkiste, MD, PhD, of Catholic University Leuven, summarizes a session he co-chaired that included discussion of translating advances in stage IV disease to nonmetastatic lung cancer, TKI approaches in early-stage disease, and integrating immunotherapy and TKIs in stage III disease management.
Caroline Robert, MD, PhD, of Gustave Roussy Cancer Centre, discusses two high-impact studies in stage III melanoma treatment: an update of the COMBI-AD trial examining dabrafenib and trametinib; and neoadjuvant ipilimumab and nivolumab therapy.
Suresh S. Ramalingam, MD, of the Emory University School of Medicine, summarizes the top-line lung cancer results reported at this year’s ESMO Congress, including the role of targeted treatment for early stage NSCLC, combining immunotherapy for surgically resectable disease, and immunotherapy for small–cell lung cancer as well as unresectable NSCLC.
Sibylle Lobil, MD, PhD, of the German Breast Group, discusses findings in metastatic breast cancer from the IMpassion130 trial in triple-negative disease and from the PALOMA3 and SOLAR-1 trials in hormone receptor–positive, HER2-negative disease (Abstracts LBA1_PR, LBA2_PR, LBA3_PR).
Nicholas D. James, PhD, MBBS, of University Hospitals Birmingham NHS Trust, discusses study findings on treating metastatic castration-sensitive prostate cancer, including results on radiotherapy and abiraterone (Abstract LBA5_PR).
Jeffrey S. Weber, MD, PhD, of the NYU Langone Perlmutter Cancer Center, discusses how long people with melanoma should be treated with PD-1 blockade and the data on remission rates.